AFP and hepatocellular carcinoma: Consistent with other reports, a specificity around 95.12%–96.3% revealed the superior discriminating power of PIVKA‐II under the context of CHB and cirrhosis than AFP, supporting the opinion that PIVKA‐II is more specific for HCC surveillance in HBV‐related high‐risk patients.